aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Comanche Biopharma is a biopharmaceutical company focused on developing siRNA therapies to treat preeclampsia, aiming to make pregnancies safer and allow for proper fetal maturation. Their mission is to create globally accessible treatments targeting the root causes of preeclampsia, reducing risks associated with pregnancy and prematurity.
Comanche Biopharma has made significant strides in preclinical development, working towards the first investigational siRNA medicine for preterm preeclampsia. Their vision is to ensure all women and their babies have access to safe, effective, and evidence-based therapies for life-threatening pregnancy complications.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics
Technology
Biotech, Sirna
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Comanche Biopharma founded?
Comanche Biopharma was founded in 2020.
Where is Comanche Biopharma's headquarters located?
Comanche Biopharma's headquarters is located in Concord, MA, US.
When was Comanche Biopharma's last funding round?
Comanche Biopharma's most recent funding round was for $75M (USD) in January 2024.
How many employees does Comanche Biopharma have?
Comanche Biopharma has 14 employees as of Feb 5, 2024.
How much has Comanche Biopharma raised to-date?
As of July 05, 2023, Comanche Biopharma has raised a total of $111.1M (USD) since Jan 17, 2024.
Add Comparison
Total Raised to Date
$111.1M
USD
Last Update Jan 17, 2024
Last Deal Details
$75M
USD
Jan 17, 2024
Series B
Total Employees Over Time
14
As of Feb 2024
Comanche Biopharma Address
50 Beharrell Street
# 50 B
Concord,
Massachusetts
01742
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts